Document is current
Any future updates will be listed below
-
Authors
Garland, Eric L.
Gullapalli, Bhanu T.
Prince, Kort C.
Hanley, Adam W.
Sanyer, Mathias
Tuomenoksa, Mark
Rahman, Tauhidur
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA042033)
- License Information
-
More Information
Article History
Accepted: 15 April 2023
First Online: 24 May 2023
Declarations
:
: The University of Utah provided IRB approval for the study.
: Participants gave written, informed consent to participate in this study.
: Eric Garland, PhD, LCSW is the Director of the Center on Mindfulness and Integrative Health Intervention Development. The Center provides Mindfulness-Oriented Recovery Enhancement (MORE), mindfulness-based therapy, and cognitive behavioral therapy in the context of research trials for no cost to research participants; however, Dr. Garland has received payment for delivering lectures, and teaching engagements (related to training clinicians in mindfulness) sponsored by institutions of higher education, government agencies, and medical centers. Dr. Garland also receives royalties from the sale of books related to MORE. Dr. Garland is a licensor to BehaVR, LLC. Mark Tuomenoksa is the Chief Technology Officer of Illumivu. No other authors have any related conflicts of interest to disclose.
: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
